|
15 Jan 2019 |
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody
|
|
15 Jan 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)
|
|
15 Jan 2019 |
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
|
|
15 Jan 2019 |
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
|
|
12 Jan 2019 |
OncoImmune Announces Completion of Phase II Trial
|
|
10 Jan 2019 |
BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149
|
|
08 Jan 2019 |
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
|
|
07 Jan 2019 |
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody
|
|
07 Jan 2019 |
Merus Announces IND Clearance for MCLA-145
|
|
07 Jan 2019 |
CytomX Therapeutics Announces Technology Acquisition From Agensys, Inc., an Affiliate of Astellas Pharma Inc.
|
|
07 Jan 2019 |
Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
|
|
07 Jan 2019 |
Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS
|
|
07 Jan 2019 |
Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA® (ustekinumab) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
|
|
07 Jan 2019 |
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
|
|
03 Jan 2019 |
Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer
|
|
03 Jan 2019 |
Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
03 Jan 2019 |
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
|
|
03 Jan 2019 |
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer
|
|
03 Jan 2019 |
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer
|
|
28 Dec 2018 |
JHL Biotech Announces First Patient Randomized in the Phase III Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma
|
|
27 Dec 2018 |
Bio-Thera Solutions Files IND for Phase 1 Clinical Trial with BAT8003 (Trop2-ADC) as Treatment for Trop2 Positive Cancers
|
|
27 Dec 2018 |
China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) for Hodgkin's Lymphoma
|
|
27 Dec 2018 |
TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors
|
|
27 Dec 2018 |
TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer
|
|
26 Dec 2018 |
I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2
|
